CHICAGO TRUST Co NA bought a new stake in Biogen Inc (NASDAQ:BIIB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,323 shares of the biotechnology company’s stock, valued at approximately $740,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Sicart Associates LLC acquired a new stake in shares of Biogen during the fourth quarter worth $446,000. National Pension Service raised its holdings in shares of Biogen by 1.0% during the fourth quarter. National Pension Service now owns 178,319 shares of the biotechnology company’s stock worth $56,807,000 after purchasing an additional 1,796 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Biogen by 21.4% during the fourth quarter. Bank of Montreal Can now owns 246,846 shares of the biotechnology company’s stock worth $78,638,000 after purchasing an additional 43,465 shares during the last quarter. Ipswich Investment Management Co. Inc. raised its holdings in shares of Biogen by 6.2% during the fourth quarter. Ipswich Investment Management Co. Inc. now owns 5,936 shares of the biotechnology company’s stock worth $1,891,000 after purchasing an additional 346 shares during the last quarter. Finally, Davis R M Inc. raised its holdings in shares of Biogen by 20.3% during the fourth quarter. Davis R M Inc. now owns 1,126 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 190 shares during the last quarter. Institutional investors own 88.14% of the company’s stock.
Several research analysts recently issued reports on the stock. Royal Bank of Canada reissued a “hold” rating and set a $321.00 target price on shares of Biogen in a report on Tuesday, December 5th. Nomura raised their target price on shares of Biogen from $355.00 to $420.00 and gave the stock a “buy” rating in a report on Saturday, December 30th. BidaskClub raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Mizuho set a $400.00 target price on shares of Biogen and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, Morgan Stanley raised shares of Biogen from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $311.00 to $375.00 in a report on Thursday, October 5th. Nine analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $353.75.
In related news, CEO Michel Vounatsos bought 780 shares of the business’s stock in a transaction dated Saturday, December 29th. The stock was acquired at an average price of $320.55 per share, with a total value of $250,029.00. Following the completion of the purchase, the chief executive officer now directly owns 4,879 shares of the company’s stock, valued at $1,563,963.45. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert W. Pangia sold 5,832 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the sale, the director now directly owns 23,539 shares of the company’s stock, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. Insiders have bought 31,560 shares of company stock valued at $10,020,858 in the last three months. Corporate insiders own 0.25% of the company’s stock.
Biogen Inc (NASDAQ:BIIB) traded up $5.93 during mid-day trading on Wednesday, hitting $344.78. 653,145 shares of the stock were exchanged, compared to its average volume of 1,188,020. The stock has a market capitalization of $73,070.00, a PE ratio of 21.14, a P/E/G ratio of 1.91 and a beta of 0.73. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46. Biogen Inc has a twelve month low of $244.28 and a twelve month high of $348.84.
Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.70 by $0.61. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.19 earnings per share. equities research analysts expect that Biogen Inc will post 21.99 earnings per share for the current year.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.